The ALS Center for Cell Therapy and Regeneration Research at Johns Hopkins is committed to identifying the causes of the neurodegenerative disease, amyotrophic lateral sclerosis (ALS), and discovering new and effective treatment options. At the ALS Center, Johns Hopkins researchers work with other investigators, including those at the Robert Packard Center for ALS Research at Johns Hopkins and clinicians within the Johns Hopkins ALS Clinic to aggressively take groundbreaking scientific discoveries and turn them into clinical applications that will improve the quality of life of those diagnosed with ALS.
The Cardiac Bioelectric Systems Laboratory research focuses on both the physiological and pathophysiological function of cardiac cells at a multicellular, syncytial level. We use cell culture models in a manner akin to mathematical models in which elements of the model can be designed, synthesized or controlled.
Our traditional approach consists of cultured, confluent monolayers of cardiac cells that number in the tens of thousands to a million. These cell monolayers can be engineered in terms of their tissue architecture, cell type, protein expression and microenvironment, and have been used to study clinically relevant phenomena in the heart that include electrical stimulation, electrical propagation, arrhythmia and cell therapy.
The Ivan Borrello Lab focuses on the development of a novel approach of adoptive T cell therapy utilizing marrow-infiltrating lymphocytes (MILs) as a more tumor-specific T cell approach. This has led to establishing the first adoptive T cell trials at Johns Hopkins and an exploration of this approach in other diseases, including nonhematologic malignancies. The lab also examines strategies for treating minimal residual disease (MRD) in myeloma with the combination of immune modulation and whole cell-based vaccines.
Dr. Amir Kashani and his team are developing novel diagnostic and therapeutic methods to diagnose and treat retinal diseases using advanced imaging methods. These methods can detect the earliest changes in retinal capillaries before they are noticeable to the patient or doctor.
The Konig Lab focuses on chimeric T cell- and antibody-based strategies for the treatment of autoimmune rheumatic diseases and cancer. A primary goal of the translational research program is the development of antigen-specific and personalized immunotherapies for autoimmune diseases, with the intent to achieve sustained disease remission and functional cure. The lab further aims to establish precision T cell-targeting therapies for the treatment of various autoimmune diseases. Applying these tools to immuno-oncology, the lab utilizes cellular engineering strategies to augment the cytotoxic killing of solid cancers by the immune system.